BLFS Biolife Solutions Inc
Price (delayed)
$25.28
Market cap
$1.19B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.44
Enterprise value
$1.12B
BioLife Solutions is a leading supplier of cell and gene therapy bioproduction products and services. Its products and services portfolio includes its proprietary CryoStor® freeze media, HypoThermosol® shipping and storage
Highlights
BLFS's quick ratio has soared by 183% year-on-year and by 113% since the previous quarter
The EPS has surged by 72% year-on-year and by 66% since the previous quarter
The company's revenue rose by 8% YoY but it fell by 2.6% QoQ
Key stats
What are the main financial stats of BLFS
Market
Valuations
Earnings
Shares outstanding
47M
Market cap
$1.19B
Enterprise value
$1.12B
Price to earnings (P/E)
N/A
Price to book (P/B)
3.36
Price to sales (P/S)
14.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.65
Revenue
$82.25M
Gross profit
$53.67M
Operating income
-$7.13M
Net income
-$20.18M
EBIT
-$19.5M
EBITDA
-$10.42M
Free cash flow
$3.14M
Per share
Balance sheet
Liquidity
EPS
-$0.44
EPS diluted
-$0.44
Free cash flow per share
$0.07
Book value per share
$7.52
Revenue per share
$1.79
TBVPS
$3.86
Total assets
$399.49M
Total liabilities
$50.58M
Debt
$30.17M
Equity
$348.91M
Working capital
$116.03M
Debt to equity
0.09
Current ratio
4.54
Quick ratio
3.48
Net debt/EBITDA
6.26
Margins
Efficiency
Dividend
EBITDA margin
-12.7%
Gross margin
65.3%
Net margin
-24.5%
Operating margin
-8.7%
Return on assets
-5.2%
Return on equity
-6.1%
Return on invested capital
-17.6%
Return on capital employed
-5.3%
Return on sales
-23.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BLFS stock price
How has the Biolife Solutions stock price performed over time
Intraday
-3.77%
1 week
-5.67%
1 month
-6.85%
1 year
43.55%
YTD
-2.62%
QTD
-2.62%
Financial performance
How have Biolife Solutions's revenue and profit performed over time
Revenue
$82.25M
Gross profit
$53.67M
Operating income
-$7.13M
Net income
-$20.18M
Gross margin
65.3%
Net margin
-24.5%
The operating margin has plunged by 102% from the previous quarter but it has soared by 74% YoY
BLFS's operating income has shrunk by 98% QoQ but it has soared by 72% YoY
The net margin has surged by 73% year-on-year and by 56% since the previous quarter
BLFS's net income has surged by 70% year-on-year and by 58% since the previous quarter
Growth
What is Biolife Solutions's growth rate over time
Valuation
What is Biolife Solutions stock price valuation
P/E
N/A
P/B
3.36
P/S
14.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
13.65
The EPS has surged by 72% year-on-year and by 66% since the previous quarter
BLFS's price to book (P/B) is 13% higher than its last 4 quarters average of 3.1 and 9% higher than its 5-year quarterly average of 3.2
The equity has grown by 7% from the previous quarter and by 3.3% YoY
The P/S is 14% higher than the last 4 quarters average of 12.9 and 11% higher than the 5-year quarterly average of 13.2
The company's revenue rose by 8% YoY but it fell by 2.6% QoQ
Efficiency
How efficient is Biolife Solutions business performance
The return on sales has surged by 73% year-on-year and by 57% since the previous quarter
The ROE has soared by 69% YoY and by 58% from the previous quarter
Biolife Solutions's return on assets has surged by 68% YoY and by 57% QoQ
The ROIC has soared by 58% YoY and by 51% from the previous quarter
Dividends
What is BLFS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BLFS.
Financial health
How did Biolife Solutions financials performed over time
BLFS's quick ratio has soared by 183% year-on-year and by 113% since the previous quarter
BLFS's current ratio has surged by 63% since the previous quarter and by 59% year-on-year
The debt is 91% smaller than the equity
Biolife Solutions's debt to equity has decreased by 25% from the previous quarter and by 10% YoY
The debt has declined by 23% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.